PMID- 31114652
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220408
IS  - 2008-2010 (Print)
IS  - 2008-322X (Electronic)
IS  - 2008-322X (Linking)
VI  - 14
IP  - 2
DP  - 2019 Apr-Jun
TI  - The Effect of Panretinal Photocoagulation (PRP) versus Intravitreal Bevacizumab 
      (IVB) Plus PRP on Peripapillary Retinal Nerve Fiber Layer (RNFL) Thickness 
      Analyzed by Optical Coherence Tomography in Patients with Proliferative Diabetic 
      Retinopathy.
PG  - 157-163
LID - 10.4103/jovr.jovr_160_17 [doi]
AB  - PURPOSE: The current study aimed to evaluate changes in peripapillary retinal 
      nerve fiber layer (RNFL) thickness in diabetic patients with bilateral 
      proliferative diabetic retinopathy (PDR) after receiving panretinal 
      photocoagulation (PRP) or intravitreal bevacizumab (IVB) with PRP. METHODS: 
      Ocular examination and peripapillary optical coherent tomography (OCT) were 
      performed for each patient at baseline, 1, 3, 6, and 10 months after treatment. 
      Both eyes of each patient were randomized into either PRP or PRP + IVB group. 
      RESULTS: Sixty-four eyes (32 patients) were enrolled in this randomized clinical 
      trial. In the PRP group, global RNFL thickness initially increased and reached 
      statistical significance in the third month (from 105.9 +/- 21.4mum at baseline to 
      119 +/- 41.6mum at 3 months, P = 0.03). Subsequent decline was observed with no 
      significant difference from baseline at 10 months (106 +/- 19.3mum, P = 0.914). 
      There were no statistically significant changes in the PRP + IVB group (from 
      101.7 +/- 22.2mum at baseline to 109.3 +/- 26.9mum at 3 months, P = 0.996 and 101.9 +/- 
      16.5mum at 10 months, P = 0.999). In the latter group, slight increase in RNFL 
      thickness was observed in the first month (107.7 +/- 21.1mum). RNFL thickness was 
      similar to baseline in the two groups at month 10, with the exception of 
      significant increase in superior-temporal sector in the PRP group (145.3 +/- 13.4mum 
      vs. 127.2 +/- 17.3mum, P = 0.045). CONCLUSION: Compared to eyes treated with PRP, 
      eyes treated with adjunctive IVB showed less significant post-treatment changes 
      in RNFL thickness.
FAU - Roohipour, Ramak
AU  - Roohipour R
AUID- ORCID: 0000-0003-3186-1922
AD  - Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, 
      Tehran, Iran.
AD  - Department of Ophthalmology, Retina Service, Massachusetts Eye and Ear Infirmary, 
      Harvard Medical School, 25 Shattuck Street, Boston, MA, New England.
FAU - Sharifian, Elahe
AU  - Sharifian E
AD  - Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, 
      Tehran, Iran.
FAU - Moghimi, Sasan
AU  - Moghimi S
AD  - Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, 
      Tehran, Iran.
FAU - Fard, Masoud Aghsaei
AU  - Fard MA
AD  - Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, 
      Tehran, Iran.
FAU - Ghassemi, Fariba
AU  - Ghassemi F
AD  - Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, 
      Tehran, Iran.
FAU - Zarei, Mohammad
AU  - Zarei M
AD  - Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, 
      Tehran, Iran.
FAU - Davoodi, Samaneh
AU  - Davoodi S
AD  - Department of Ophthalmology, Retina Service, Massachusetts Eye and Ear Infirmary, 
      Harvard Medical School, 25 Shattuck Street, Boston, MA, New England.
FAU - Bazvand, Fatemeh
AU  - Bazvand F
AUID- ORCID: 0000-0001-9720-2028
AD  - Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, 
      Tehran, Iran.
FAU - Modjtahedi, Bobeck S
AU  - Modjtahedi BS
AD  - Department of Ophthalmology, Retina Service, Massachusetts Eye and Ear Infirmary, 
      Harvard Medical School, 25 Shattuck Street, Boston, MA, New England.
LA  - eng
PT  - Journal Article
PL  - United Arab Emirates
TA  - J Ophthalmic Vis Res
JT  - Journal of ophthalmic & vision research
JID - 101497643
PMC - PMC6504732
OTO - NOTNLM
OT  - Bevacizumab
OT  - Diabetes
OT  - Panretinal Photocoagulation
OT  - Retinal Nerve Fiber Layer
OT  - Retinopathy
COIS- All authors certify that have no financial interests.
EDAT- 2019/05/23 06:00
MHDA- 2019/05/23 06:01
PMCR- 2019/04/01
CRDT- 2019/05/23 06:00
PHST- 2019/05/23 06:00 [entrez]
PHST- 2019/05/23 06:00 [pubmed]
PHST- 2019/05/23 06:01 [medline]
PHST- 2019/04/01 00:00 [pmc-release]
AID - JOVR-14-157 [pii]
AID - 10.4103/jovr.jovr_160_17 [doi]
PST - ppublish
SO  - J Ophthalmic Vis Res. 2019 Apr-Jun;14(2):157-163. doi: 10.4103/jovr.jovr_160_17.